The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Statins Linked to Reduced Likelihood of Joint Replacement

Statins Linked to Reduced Likelihood of Joint Replacement

March 16, 2020 • By Reuters Staff

  • Tweet
  • Email
Print-Friendly Version / Save PDF

NEW YORK (Reuters Health)—High-intensity statins are associated with a lower risk of joint replacement, new findings show.

You Might Also Like
  • Statins & the Risk of RA
  • Statins Linked to Idiopathic Inflammatory Myositis
  • Statins May Protect Against RA

“Statins at high intensity may reduce the risk of hip and knee replacement. The effect may be RA specific,” Dr. Aliya Sarmanova of the University of Nottingham, U.K., and colleagues write in Rheumatology.1

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Statins have anti-inflammatory effects, and there is some evidence linking them to reduced disease activity in patients with rheumatoid arthritis (RA), the authors note. Studies of statins and osteoarthritis (OA) have had more mixed results.

Using electronic health records from a UK primary care database, the authors matched more than 178,000 statin users to non-users by propensity score. Mean follow-up was 6.88 years for statin users and 6.25 years for non-users.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Statin-treatment intensity was classified based on potency of LDL-cholesterol reduction: low intensity (21–28%); medium (32–38%); or high (42–55%). About three-quarters of study participants were on medium-intensity treatment.

Statin use was not associated with knee joint replacement (KJR), hip joint replacement (HJR) or joint replacement due to OA. But statin users who had RA had a significantly reduced likelihood of joint replacement compared to non-statin-using RA patients (hazard ratio: 0.77).

Patients on high-intensity statins were at reduced risk of any joint replacement (HR, 0.86), joint replacement due to RA (HR, 0.10) and joint replacement for OA (HR 0.79).

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

There was a trend toward a dose-response effect for overall joint replacement and knee joint replacement.

Although the effect was small and may not be clinically significant, “at this early stage we believe that a statistical significance should not be ignored,” Dr. Sarmanova and her colleagues write.

“Given the limitations of this study, further well designed studies are still needed to examine the mechanism of statins in RA,” they add. “A randomized controlled trial to assess the efficacy and cost-effectiveness of different treatment regimens of statin with or without other anti-rheumatic drugs in people with RA and CVDs or at high risk of CVDs is also justified.”

The study had no commercial funding, and the researchers report no ties to manufacturers.


Reference

  1. Sarmanova A, Doherty M, Kuo C, et al. Statin use and risk of joint replacement due to osteoarthritis and rheumatoid arthritis: A propensity-score matched longitudinal cohort study. Rheumatology (Oxford). 2020 Feb 25. pii: keaa044. [Epub ahead of print]

Filed Under: Conditions Tagged With: joint, joint replacement, Statin, statin treatment

You Might Also Like:
  • Statins & the Risk of RA
  • Statins Linked to Idiopathic Inflammatory Myositis
  • Statins May Protect Against RA
  • Get the Most Out of Joint Replacement

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)